NASDAQ:INCR InterCure (INCR) Stock Price, News & Analysis $1.60 -0.08 (-4.76%) Closing price 04:00 PM EasternExtended Trading$1.60 0.00 (0.00%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About InterCure Stock (NASDAQ:INCR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get InterCure alerts:Sign Up Key Stats Today's Range$1.56▼$1.6850-Day Range$1.44▼$1.7352-Week Range$1.17▼$1.87Volume30,057 shsAverage Volume34,485 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health. Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives. The company’s in-house R&D team works in collaboration with academic and medical institutions to explore novel therapeutic applications of cannabinoids. InterCure’s product portfolio includes standardized oils, capsules and topical formulations designed to address specific clinical indications and patient preferences. Beyond its domestic footprint, InterCure has entered strategic partnerships aimed at exporting medical cannabis products to select European and Latin American markets. These collaborations are structured to meet local regulatory requirements and quality standards, offering a pathway for InterCure’s intellectual property and high-potency strains to reach new patient populations. Looking forward, InterCure is focused on scaling its production capacity, enhancing process efficiencies and expanding its international presence through licensing agreements and joint ventures. The company continues to invest in clinical research, advanced processing technologies and new product development as it seeks to establish a broader footprint in the evolving global medical cannabis industry.AI Generated. May Contain Errors. Read More InterCure Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreINCR MarketRank™: InterCure scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for InterCure.Read more about InterCure's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioInterCure has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.07% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently decreased by 39.60%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInterCure does not currently pay a dividend.Dividend GrowthInterCure does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.07% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently decreased by 39.60%, indicating that investor sentiment is improving significantly. News and Social Media2.7 / 5News Sentiment0.80 News SentimentInterCure has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for InterCure this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added InterCure to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, InterCure insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.24% of the stock of InterCure is held by insiders.Percentage Held by InstitutionsOnly 8.34% of the stock of InterCure is held by institutions.Read more about InterCure's insider trading history. Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INCR Stock News HeadlinesInterCure Ltd.: InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash FlowOctober 8 at 3:20 PM | finanznachrichten.deInterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash FlowOctober 8 at 9:40 AM | globenewswire.comGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" Eifrig says history shows it could be on the verge of its biggest bull run in over half a century.October 10 at 2:00 AM | Stansberry Research (Ad)InterCure Ltd. Reports NIS 130 Million in Revenue and Sustains Profitability with Eleventh Consecutive Half of Positive Adjusted EBITDAOctober 8 at 9:31 AM | quiverquant.comQInterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash FlowOctober 8 at 9:02 AM | globenewswire.comInterCure To Buy ISHI In All-Stock Transaction – Find Out MoreSeptember 19, 2025 | msn.comInterCure Enters Premium US Cannabis Market With ISHI DealSeptember 19, 2025 | benzinga.comInterCure Acquires ISHI to Expand U.S. Cannabis Market ReachSeptember 19, 2025 | tipranks.comSee More Headlines INCR Stock Analysis - Frequently Asked Questions How have INCR shares performed this year? InterCure's stock was trading at $1.59 at the beginning of 2025. Since then, INCR stock has decreased by 0.9% and is now trading at $1.5750. How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of InterCure own? Based on aggregate information from My MarketBeat watchlists, some other companies that InterCure investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), Advanced Micro Devices (AMD), Tesla (TSLA), Innovative Industrial Properties (IIPR) and AbbVie (ABBV). Company Calendar Today10/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED PRODUCTS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:INCR CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees350Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$64.55 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.36 per share Price / Book0.67Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableOptionable Beta1.20 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:INCR) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredU.S. Government Sparking Crypto RallyAltcoin ETFs could surge prices (do this now) My "Crypto Bull Run Millionaire Blueprint" breaks down exactl...Crypto 101 Media | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share InterCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.